|6 Months Ended|
Jun. 30, 2023
|Goodwill and Intangible Assets Disclosure [Abstract]|
NOTE 4 – LICENSED TECHNOLOGY
On May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children’s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is amortized to expense over the life of the license of 20 years. On March 31, 2022, the Company announced that it was pursuing a strategic partner to take over development activities of ABO-102 and that it was discontinuing development of ABO-101. As a result of this shift in priorities, the Company determined the remaining value of the licensed technology had future value and thus, recorded an impairment charge of $1.4 million for the six months ended June 30, 2022. There is no remaining net value of licensed technology as of June 30, 2023 and December 31, 2022.
Amortization expense on licensed technology was and $29,000 for the six months ended June 30, 2023 and 2022, respectively. There was no amortization expense for the three months ended June 30, 2023 or 2022.
The entire disclosure for all or part of the information related to intangible assets.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef